Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment.

Med Sci (Basel) · 2018 · PMC6313620 · PMID 30274295

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Bevacizumab prolonged survival, as did an ACE inhibitor or ARB, but increased survival by the addition of an ACE inhibitor/ARB to bevacizumab did not reach statistical significance for additive effect [ 65 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.